Updated:
Virginia Biosciences Health Research Corporation
Virginia Biosciences Health Research Corporation (VBHRC) was established in 2012 as a nonprofit entity formed by major research universities across...
Virginia Biosciences Health Research Corporation
Virginia Biosciences Health Research Corporation (VBHRC) was established in 2012 as a nonprofit entity formed by major research universities across Virginia to facilitate translational research and economic development in the life sciences. The organization's founding was supported by a combination of state funding, university commitments, and federal research grants — designed to create a pipeline from laboratory discoveries to commercially viable therapies and diagnostic tools (per public record). VBHRC's strategy centers on funding and managing pre-clinical and clinical-stage projects arising from its university partners — including the University of Virginia, Virginia Commonwealth University, and Virginia Tech. The entity provides gap funding, project management, and regulatory expertise to advance candidate therapeutics, medical devices, and diagnostics through milestones that attract industry partners or follow-on investment. Known project areas include oncology, infectious disease, and neurological disorders (per public record). VBHRC operates primarily within Virginia, with its headquarters in Virginia Beach and lab facilities linked to its partner universities across the state. The team size is not publicly disclosed but includes a small core of scientific managers and business development professionals. In 2022, VBHRC announced a partnership with the Commonwealth of Virginia's GO Virginia program to expand its capacity for industry-university collaboration (per public record). A structural differentiator is VBHRC's formal role as a university-led consortium rather than a standalone venture fund or CRO. Its governance includes representatives from each partner university, ensuring that research decisions are aligned with academic mission while maintaining a commercial orientation. This model, sometimes described as a translational research accelerator, allows VBHRC to manage intellectual property and licensing across multiple institutions from a single coordinating entity.
General information
Firm type
University-affiliated Translational Research Entity
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Virginia Beach
Corporate office
Virginia Beach, VA, United States
Principals
J. Paul Gilman
Chief Executive Officer
Jeffrey W. Sherman
Vice President, Clinical Research
Sector focus
Frequently asked questions
How does VBHRC differ from a traditional venture capital firm investing in life sciences?
VBHRC is a nonprofit consortium formed by Virginia's research universities to manage translational research, rather than a for-profit VC. It provides gap funding and project management to de-risk academic discoveries, not direct equity investment. Its goal is to advance projects to a point where they attract commercial partners or follow-on investment from venture firms or pharmaceutical companies (per the firm's public description).
Which universities are partner institutions in the VBHRC consortium?
VBHRC's founding members include the University of Virginia, Virginia Commonwealth University, Virginia Tech, and James Madison University. These institutions contribute faculty researchers, laboratory space, and a share of the project pipeline. Additional partner institutions may participate on a project-specific basis (per public record).
What types of projects does VBHRC typically fund or manage?
VBHRC supports early-stage translational projects spanning therapeutics, medical devices, and diagnostics. The focus is on projects with a clear path to clinical validation and commercial licensing. Past project areas include oncology, infectious disease, and neurological disorders. The organization does not typically fund basic research or late-stage commercialization (per public record).
Does VBHRC accept external investment or operate as a fund?
VBHRC is a nonprofit entity and does not raise capital from external limited partners as a venture fund would. It receives state funding, university contributions, and federal grants to support its operations. While it may license intellectual property to commercial entities, it does not issue equity or return capital in a traditional fund structure (per public record).
How does VBHRC measure its success?
Successful outcomes typically involve projects that achieve clinical trial milestones, receive FDA clearance or approval, or are licensed to pharmaceutical or medtech companies. Additionally, creation of spinout startup companies and job growth in Virginia's life sciences sector are considered key performance indicators (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: